Clinical efficacy of Xintongshu spray combined with conventional western medicine treatment for coronary artery disease patients with arrhythmia and electrocardiogram abnormalities
心痛舒喷雾剂联合西医常规治疗心律失常及心电图异常冠心病患者的临床疗效

摘要

目的 观察心痛舒喷雾剂联合西医常规治疗心律失常及心电图异常冠心病患者的临床疗效。方法 纳入2023年9月-2025年8月收治的298例患者，分联合组与对照组各149例，疗程1周。比较两组心绞痛发作、心电图改善、心功能、生命体征及痰热、热毒、血瘀积分变化。结果 联合组心绞痛显效率78.52%，高于对照组的55.70%（P＜0.001）；心电图显效率72.48%vs51.68%（P＜0.001）。治疗后联合组LVEF（58.32±4.21）%高于对照组（53.06±4.35）%（P＜0.001），LVESD、LVDD、CI亦改善更显著（P＜0.05）。联合组痰热、热毒、血瘀积分下降幅度均优于对照组（P＜0.01）。结论 心痛舒喷雾剂联合常规治疗可显著改善心绞痛症状、心电图异常与心功能，具有优势且安全性良好。

Abstract

Objective To observe the clinical efficacy of Xintongshu spray combined with conventional Western medicine treatment for coronary artery disease patients with arrhythmia and electrocardiogram abnormalities.
Methods 298 patients admitted from September 2023 to August 2025 were included, divided into a combined treatment group and a control group, with 149 patients in each group. The treatment course was 1 week. Changes in angina attacks, electrocardiogram improvement, cardiac function, vital signs, and phlegm-heat, heat-toxin, and blood stasis scores were compared between the two groups.
Results The effective rate of angina in the combined treatment group was 78.52%, which was higher than that in the control group (55.70%) (P<0.001); the effective rate of electrocardiogram was 72.48% vs 51.68% (P<0.001). After treatment, the combined treatment group showed a significantly higher LVEF (58.32±4.21)% compared to the control group (53.06±4.35)% (P<0.001), with more significant improvements in LVESD, LVDD, and CI (P<0.05). The combined treatment group also showed a greater reduction in phlegm-heat, heat-toxin, and blood stasis scores compared to the control group (P<0.01).
Conclusion   The combination of Xintongshu spray and conventional treatment can significantly improve angina symptoms, ECG abnormalities, and cardiac function, demonstrating advantages and good safety.